Acadian Asset Management
BBOT

Acadian Asset Management’s BridgeBio Oncology BBOT Stock Holding History

Acadian Asset Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,148
Closed -$260K – 2285
2026
Q1 		$260K Buy
+29,148
New +$313K ﹤0.01% 1521

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management's BBOT Position: Q2 2026 in Review

Acadian Asset Management sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 29,148 shares — an estimated $260K sold.

Acadian Asset Management first reported a position in BBOT in Q1 2026 and held it in 1 quarter. The position peaked at $260K in Q1 2026. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Acadian Asset Management reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 29,148 BridgeBio Oncology shares in Q2 2026, an estimated $260K.
  • Acadian Asset Management first reported a position in BridgeBio Oncology in Q1 2026 and held it in 1 quarter.
  • Acadian Asset Management's BridgeBio Oncology position peaked at $260K in Q1 2026.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.